Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
A Study of Gemcitabine/Cisplatin Plus Cemiplimab (REGN2810, Anti-PD-1) With or Without Fianlimab (REGN3767, Anti-LAG-3) in Patients With Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 36
- Registration Number
- NCT06571708
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT06564844
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49%
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 800
- Registration Number
- NCT06561386
- Locations
- 🇺🇸
Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States
🇺🇸Local Institution - 0369, Canton, Ohio, United States
🇧🇷Local Institution - 0382, Fortaleza, Ceará, Brazil
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06548412
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Chemoimmunotherapy Combined with Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 15
- Registration Number
- NCT06546969
- Locations
- 🇺🇸
Maryland Proton Treatment Center, Baltimore, Maryland, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06543576
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Diego (UCSD), San Diego, California, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- The National Center of Oncology, Azerbaijan
- Target Recruit Count
- 200
- Registration Number
- NCT06531447
- Locations
- 🇦🇿
Elchin Mansurov, Baku, Azerbaijan
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaNasopharyngeal Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaStage 0 Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Interventions
- Other: Best PracticeProcedure: Biospecimen CollectionDrug: CisplatinProcedure: Computed TomographyRadiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingDrug: Placebo AdministrationDrug: MnSOD Mimetic BMX-001Other: Questionnaire Administration
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 98
- Registration Number
- NCT06532279
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 143
- Registration Number
- NCT06510465
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 700
- Registration Number
- NCT06493552
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.